Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Jason O’Byrne became CFO, principal financial officer and principal accounting officer effective August 11, 2026.
Olema Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jason O’Byrne became CFO, principal financial officer and principal accounting officer effective August 11, 2026
- Leadership experience includes Vir Biotechnology, Caribou Biosciences, Audentes Therapeutics and Roche, strengthening biopharma finance expertise
- Annual base salary $545,000, with a 45% target performance bonus
- Sign-on bonus totals $350,000, split between $250,000 after appointment and $100,000 after one year
- Proposed inducement option for 650,000 shares, vesting over four years and creating potential shareholder dilution
Item 7.01 · Regulation FD Disclosure
- Olema appointed Mr. O’Byrne as Chief Financial Officer effective August 13, 2026
- CFO appointment may affect financial strategy, capital planning and investor communications
- Leadership change is material for a clinical-stage biotechnology company reliant on external financing
Item EX-99.1 · Exhibit EX-99.1
- Jason O’Byrne appointed CFO, succeeding prior finance leadership as Olema approaches pivotal OPERA-01 data
- Executive brings IPO, capital markets, acquisition integration, and commercial-stage biotechnology experience
- Appointment supports potential palazestrant launch and transition toward a fully integrated oncology company
- Near-term investor focus: OPERA-01 Phase 3 data, palazestrant launch readiness, and capital allocation under new CFO നേതൃത്വ
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Olema Pharmaceuticals, Inc. 8-K filings
Get the next OLMA 8-K as it lands
Follow OLMA for push alerts, or ask the research agent what this filing means.